The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity

被引:0
|
作者
Wenjing Gu
Hui Gan
Yu Ma
Lina Xu
Zhangkai J. Cheng
Bizhou Li
Xinxing Zhang
Wujun Jiang
Jinlv Sun
Baoqing Sun
Chuangli Hao
机构
[1] Children’s Hospital of Soochow University,Department of Respiration
[2] Guangzhou Institute of Respiratory Health,National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease
[3] Peking Union Medical College,Department of Allergy, Peking Union Hospital
来源
关键词
SARS-CoV-2; COVID-19; Antiviral innate immunity; Molecular mechanism; PRR;
D O I
暂无
中图分类号
学科分类号
摘要
The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has resulted in a global health emergency (COVID-19) because of its rapid spread and high mortality. Since the virus epidemic, many pathogenic mechanisms have been revealed, and virus-related vaccines have been successfully developed and applied in clinical practice. However, the pandemic is still developing, and new mutations are still emerging. Virus pathogenicity is closely related to the immune status of the host. As innate immunity is the body’s first defense against viruses, understanding the inhibitory effect of SARS-CoV-2 on innate immunity is of great significance for determining the target of antiviral intervention. This review summarizes the molecular mechanism by which SARS-CoV-2 escapes the host immune system, including suppressing innate immune production and blocking adaptive immune priming. Here, on the one hand, we devoted ourselves to summarizing the combined action of innate immune cells, cytokines, and chemokines to fine-tune the outcome of SARS-CoV-2 infection and the related immunopathogenesis. On the other hand, we focused on the effects of the SARS-CoV-2 on innate immunity, including enhancing viral adhesion, increasing the rate of virus invasion, inhibiting the transcription and translation of immune-related mRNA, increasing cellular mRNA degradation, and inhibiting protein transmembrane transport. This review on the underlying mechanism should provide theoretical support for developing future molecular targeted drugs against SARS-CoV-2. Nevertheless, SARS-CoV-2 is a completely new virus, and people’s understanding of it is in the process of rapid growth, and various new studies are also being carried out. Although we strive to make our review as inclusive as possible, there may still be incompleteness.
引用
收藏
相关论文
共 50 条
  • [1] The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity
    Gu, Wenjing
    Gan, Hui
    Ma, Yu
    Xu, Lina
    Cheng, Zhangkai J.
    Li, Bizhou
    Zhang, Xinxing
    Jiang, Wujun
    Sun, Jinlv
    Sun, Baoqing
    Hao, Chuangli
    VIROLOGY JOURNAL, 2022, 19 (01)
  • [2] The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2
    Aliyari, Saba R.
    Quanquin, Natalie
    Pernet, Olivier
    Zhang, Shilei
    Wang, Lulan
    Cheng, Genhong
    PATHOGENS, 2022, 11 (05):
  • [3] Role of innate immunity in SARS-CoV-2 infection
    Wang, Zihao
    Cheng, Fang
    Xu, Yuxiu
    Li, Xin
    Meng, Songdong
    BIOSAFETY AND HEALTH, 2023, 5 (05) : 280 - 288
  • [4] Innate immunity to SARS-CoV-2 infection: a review
    Abrahao Silva, Marcos Jesse
    Rodrigues, Yan Correa
    Batista Lima, Karla Valeria
    Gondim Costa Lima, Luana Nepomuceno
    EPIDEMIOLOGY AND INFECTION, 2022, 150
  • [5] Immunotherapy approaches on innate immunity for SARS-Cov-2
    Arslan, B. A.
    Timucin, A. C.
    ACTA VIROLOGICA, 2020, 64 (04) : 389 - 395
  • [6] Role of innate immunity in SARS-CoV-2 infection
    Wang Zihao
    Cheng Fang
    Xu Yuxiu
    Li Xin
    Meng Songdong
    生物安全与健康(英文), 2023, 05 (05)
  • [7] The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies
    Zhang, Shilei
    Wang, Lulan
    Cheng, Genhong
    MOLECULAR THERAPY, 2022, 30 (05) : 1869 - 1884
  • [8] Host antiviral proteins hijacked by SARS-CoV-2
    Devi, Sharmila
    LANCET INFECTIOUS DISEASES, 2022, 22 (07): : 953 - 953
  • [9] Host proviral and antiviral factors for SARS-CoV-2
    Lv, Lu
    Zhang, Leiliang
    VIRUS GENES, 2021, 57 (06) : 475 - 488
  • [10] Host proviral and antiviral factors for SARS-CoV-2
    Lu Lv
    Leiliang Zhang
    Virus Genes, 2021, 57 : 475 - 488